Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to revolutionize drug discovery and development, announced an agreement with AstraZeneca to build biopharma agents as part of their three-year licensing of K Pro ? Owkin?s AI Scientist for biopharma decision making. Agreement includes license for Owkin?s AI Scientist, K Pro, for three years.
As part of this license, Owkin will develop novel biopharma agents for AstraZeneca, usable through K Pro. This will include capabilities to quickly analyze and forecast the competitive landscape for specific pharmaceutical targets, assets, and trials. Under the three-year licensing agreement, Owkin will lead the end-to-end development of AI agents to run on K Pro, integrated within AstraZeneca?s IT infrastructure and decision workflows.
The new agents' functionality is intended to help AstraZeneca?s decision-making teams access timely, data-rich insights for complex competitive intelligence questions, reducing reliance on manual analysis within established governance, security, and enterprise standards.
